WO2026055841A1 - Composé hétérocyclique fusionné à un cycle aromatique, son procédé de préparation et son utilisation - Google Patents

Composé hétérocyclique fusionné à un cycle aromatique, son procédé de préparation et son utilisation

Info

Publication number
WO2026055841A1
WO2026055841A1 PCT/CN2024/118241 CN2024118241W WO2026055841A1 WO 2026055841 A1 WO2026055841 A1 WO 2026055841A1 CN 2024118241 W CN2024118241 W CN 2024118241W WO 2026055841 A1 WO2026055841 A1 WO 2026055841A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
mmol
independently
group
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2024/118241
Other languages
English (en)
Chinese (zh)
Inventor
施晶晶
顾越飞
吴国辉
张正
朱鑫
龚林培
汪鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cascade Pharmaceuticals Inc
Original Assignee
Cascade Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cascade Pharmaceuticals Inc filed Critical Cascade Pharmaceuticals Inc
Priority to PCT/CN2024/118241 priority Critical patent/WO2026055841A1/fr
Publication of WO2026055841A1 publication Critical patent/WO2026055841A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé hétérocyclique fusionné à un cycle aromatique, son procédé de préparation et son utilisation. Le composé hétérocyclique fusionné à un cycle aromatique de la présente invention est un composé tel que représenté par la formule (I) ou (II), ou un sel pharmaceutiquement acceptable de celui-ci. Le composé hétérocyclique fusionné à un cycle aromatique de la présente invention présente une bonne activité agoniste vis-à-vis de GPR40, et présente de bonnes perspectives pharmaceutiques.
PCT/CN2024/118241 2024-09-11 2024-09-11 Composé hétérocyclique fusionné à un cycle aromatique, son procédé de préparation et son utilisation Pending WO2026055841A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2024/118241 WO2026055841A1 (fr) 2024-09-11 2024-09-11 Composé hétérocyclique fusionné à un cycle aromatique, son procédé de préparation et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2024/118241 WO2026055841A1 (fr) 2024-09-11 2024-09-11 Composé hétérocyclique fusionné à un cycle aromatique, son procédé de préparation et son utilisation

Publications (1)

Publication Number Publication Date
WO2026055841A1 true WO2026055841A1 (fr) 2026-03-19

Family

ID=99099993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2024/118241 Pending WO2026055841A1 (fr) 2024-09-11 2024-09-11 Composé hétérocyclique fusionné à un cycle aromatique, son procédé de préparation et son utilisation

Country Status (1)

Country Link
WO (1) WO2026055841A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524466A (zh) * 2012-07-03 2014-01-22 上海昀怡健康管理咨询有限公司 二氢苯并呋喃类衍生物、其制备方法、中间体及其应用
WO2014159559A1 (fr) * 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Furanes fusionnés pour le traitement de l'hépatite c
US20170210727A1 (en) * 2014-08-08 2017-07-27 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
CN107266413A (zh) * 2017-05-09 2017-10-20 上海大学 杂环并苯丙酸衍生物及其制备方法和应用
CN108699019A (zh) * 2015-11-11 2018-10-23 华纳巴布科克绿色化学学院有限公司 用于治疗中枢神经系统和其他疾病的苯并呋喃衍生物
WO2023134712A1 (fr) * 2022-01-14 2023-07-20 Rezubio Pharmaceuticals Co., Ltd Composes antidiabétiques et compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524466A (zh) * 2012-07-03 2014-01-22 上海昀怡健康管理咨询有限公司 二氢苯并呋喃类衍生物、其制备方法、中间体及其应用
WO2014159559A1 (fr) * 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Furanes fusionnés pour le traitement de l'hépatite c
US20170210727A1 (en) * 2014-08-08 2017-07-27 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
CN108699019A (zh) * 2015-11-11 2018-10-23 华纳巴布科克绿色化学学院有限公司 用于治疗中枢神经系统和其他疾病的苯并呋喃衍生物
CN107266413A (zh) * 2017-05-09 2017-10-20 上海大学 杂环并苯丙酸衍生物及其制备方法和应用
WO2023134712A1 (fr) * 2022-01-14 2023-07-20 Rezubio Pharmaceuticals Co., Ltd Composes antidiabétiques et compositions

Similar Documents

Publication Publication Date Title
TWI606039B (zh) Ａｐｊ受體之三唑激動劑
CN105143183B (zh) 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
WO2024131777A1 (fr) Composé chimérique de kras-protac, son procédé de préparation et son utilisation
CN108017603B (zh) 三环化合物及其用途
WO2020135771A1 (fr) Intermédiaire de composé hétérocyclique, son procédé de préparation et son utilisation
WO2022268066A1 (fr) Agent de dégradation de protéine
CN101774938B (zh) 一类辣椒碱衍生物、其制备方法及其制备新型镇痛药物的用途
CN106257976A (zh) 人类血浆激肽释放酶抑制剂
CN105566265A (zh) 新颖的胰高血糖素受体拮抗剂
TW201408661A (zh) 抗病毒性化合物之固體形式
WO2023222084A1 (fr) Composé benzimidazole ou azabenzimidazole, son procédé de préparation et son utilisation
TW201410655A (zh) 咪唑啉類衍生物、其製備方法及其在醫藥上的應用
CN103421061A (zh) 来那度胺衍生物、其制法及其医药用途
WO2024109922A1 (fr) Composé de pyridazine à cycle ponté et son utilisation
WO2022117059A1 (fr) Inhibiteur à petites molécules de la cathepsine c et son utilisation médicinale
CN107162921B (zh) 一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
JP6908805B2 (ja) Ｃｎｓおよび他の障害の処置のためのベンゾフラン誘導体
CN110914248A (zh) 含有胺或(硫代)酰胺的lxr调节剂
BR112012005511B1 (pt) 5-(3,4-dicloro-fenil)-n-(2-hidróxi-ciclo-hexil)-6-(2,2,2-triflúor-etóxi-)-nicotinamida e sais da mesma como agentes de elevação de colesterol hdl
CN106748970A (zh) N‑芳基‑1‑脱氧野尻霉素衍生物及其在制备治疗糖尿病药物中的应用
JP2020508981A (ja) ビアリール化合物、その製造方法及び用途
KR20250044261A (ko) 다환계 갑상선 호르몬β 수용체 아고니스트 및 그 사용
CN104326950A (zh) 苯氧乙酸类衍生物、其制备方法及其作为药物的用途
CN104583177B (zh) 作为钙敏感受体调节剂的芳基烷基胺化合物
CN114426538A (zh) 一种小檗碱卡格列净衍生物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24954010

Country of ref document: EP

Kind code of ref document: A1